無(wú)創(chuàng)血壓計(jì)應(yīng)用論文 動(dòng)物用血壓計(jì)

 

【摘要】  Androgen has anabolic effects on cardiac myocytes and has been shown to enhance left ventricular enlargement and function. However, the physiological and patho-physiological roles of androgen in cardiac growth and cardiac stress-induced remodeling remains unclear. We aimed to clarify whether the androgen-nuclear androgen receptor (AR) system contributes to the cardiac growth and angiotensin II (Ang II)-stimulated cardiac remodeling by using systemic AR-null male mice. AR knock-out (ARKO) male mice, at 25 weeks of age, and age-matched wild-type (WT) male mice were treated with or without Ang II stimulation (2.0 mg/kg/day) for 2 weeks. ARKO mice with or without Ang II stimulation showed a significant reduction in the heart-to-body weight ratio compared with those of WT mice. In addition, echocardiographic analysis demonstrated impairments of both the concentric hypertrophic response and left ventricular function in Ang II-stimulated ARKO mice. Western blot analysis of the myocardium revealed that activation of extracellular signal-regulated kinases (ERK) 1/2 and ERK5 by Ang II stimulation were lower in ARKO mice than those of WT mice. Ang II stimulation caused more prominent cardiac fibrosis in ARKO mice than in WT mice with enhanced expression of types I and III collagen and transforming growth factor-1 genes and with increased Smad2 activation. These results suggest that, in male mice, the androgen-AR system participates in normal cardiac growth and modulates cardiac adaptive hypertrophy and fibrosis during the process of cardiac remodeling under hypertrophic stress.

【關(guān)鍵詞】  Androgen Receptor Knockout Impaired Exacerbation Angiotensin IIinduced Fibrosis

INTRODUCTION

Androgen exerts a variety of biological effects in many target organs, including male genitalia, brain, and skeletal tissues (1, 2). Most of these actions are mediated through the transcriptional control of particular sets of target genes by the nuclear androgen receptor (AR).1 AR is a ligand-inducible transcription factor that belongs to the nuclear receptor superfamily (3, 4). Upon hormone binding, AR is translocated from the cytosol into the nucleus where it binds specific promoter elements. A number of coregulators and/or coregulator complexes are then recruited to AR, which then activates or represses the transcription of various target genes (2, 3, 5-7). To clarify the physiological function of androgen via AR transcriptional regulation, we generated AR knock-out (ARKO) mice by means of the Cre-loxP system and have reported that ARKO male mice manifest late-onset obesity (8), high turnover osteopenia (9), and impaired brain masculinization (10).

In addition to the classic target tissues of androgens, the AR gene is also expressed in mammalian cardiomyocytes, suggesting that androgens may play a role in the heart (11). In fact, Marsh and colleagues (11) have shown that androgens produce cardiac hypertrophy by a direct, receptor-specific mechanism. They also revealed that androgens regulate functional expression of an L-type calcium channel in isolated rat ventricular myocytes, leading to a modulation of cardiac performance in males (12). Li et al. (13) reported that either castration or flutamide, an AR antagonist, markedly attenuated cardiac hypertrophy and fibrosis in guanylyl cyclase-A knock-out male mice. These previous studies have helped in delineating the influence of the androgen-AR system in the heart. However, to prove the physiological and pathophysiological roles of the androgen-AR system on cardiac structure and function, in vitro experiments as well as in vivo studies using pharmacological manipulations have limitations.

In the present study, to define the biological significance of cardiac AR function, we carried out studies using ARKO male mice. We obtained in vivo evidence that the androgen-AR system plays a pivotal role in normal cardiac growth and in cardiac protection against angiotensin II (Ang II)-induced cardiac fibrosis in male mice.

EXPERIMENTAL PROCEDURES

Animal Preparation-ARKO male mice were generated by targeted disruption of the AR gene using the Cre-loxP system. ARKO male mice with C57BL6/CBA hybrid backgrounds were generated and maintained as previously reported (8-10). In ARKO male mice, testicular androgen production seemed to be severely impaired, leading to a reduction in serum gonadal androgen levels, whereas serum adrenal androgen and estrogen levels remained normal (9). We used littermate wild-type (WT) male mice and ARKO male mice in this study and divided these mice into four groups; WT male mice with or without Ang II stimulation and ARKO male mice with or without Ang II stimulation. Ang II (WAKO, Japan) dissolved in saline was continuously and subcutaneously infused at a rate of 2.0 mg/kg/day for 2 weeks using an osmotic minipump (Alzet model 1002, Alza Corp., Mountain View, CA). Experiments were conducted in these male mice at 25 weeks of age. All experimental procedures were performed in accordance with the guidelines of the Animal Research Committee, The University of Tokushima Graduate School.

Measurements of Blood Pressure and Heart Rate-Systolic blood pressure and heart rate were measured using a noninvasive computerized tail-cuff system (BP98A Softron Corp., Tokyo, Japan) at 2 weeks after pump implantation. Unanesthetized mice from each group were placed in a holding device mounted on a thermostatically controlled warming plate, maintained at 37 °C. Systolic blood pressure and heart rate were measured on two consecutive days, and at least 10 readings were taken for each measurement.

Echocardiographic Analysis-Transthoracic echocardiography was performed using a 15-MHz imaging transducer (Aplio 80 Toshiba Medical Systems Co. Ltd., Japan). Mice from each group were anesthetized by peritoneal injection with 20 mg/kg of 2.5% pentobarbital. The left hemithorax of each mouse was carefully shaved, and M-mode images of the left ventricle were recorded. Left ventricular anterior wall thickness (AW), left ventricular end-diastolic dimension (LVDd), left ventricular end-systolic dimension (LVDs), and left ventricular posterior wall thickness (PW) were measured. All measurements were performed using the leading edge-to-leading edge convention adopted by the American Society of Echocardiography. Percent fractional shortening (FS), left ventricular mass (LVM), and relative wall thickness (RWT) were calculated as follows: FS = ((LVDd - LVDs)/LVDd) x 100, LVM = 1.05 x ((LVDd + AW + PW)3/1000 - LVDd3/1000 + 0.6) and RWT = (AW + PW)/LVDd.

Determination of Heart-to-Body Weight Ratio and Histological Analysis-At the end of pump infusion, mice from each group were anesthetized, and the hearts were excised. The weight of the whole heart (HW) was measured, and the ratio of HW to body weight (HW/BW) was calculated. The whole heart was resected and placed in 20% neutral buffered formalin overnight. After fixation, samples were embedded in paraffin. Then 3-µm sections were cut and stained. The cross-sectional areas of LV myocytes were measured on the mid free wall of the LV from sections stained with hematoxylin/eosin. Suitable cross-sectional areas were defined as having nearly circular capillary profiles and nuclei. Approximately 100 cells were counted in each section, and the average area was used for analysis. To calculate the ratio of the interstitial fibrosis area in the left ventricular area, excluding perivascular fibrosis, samples were stained with Masson-Trichrome and 10 fields were randomly selected from 3 individual sections. Measurements of both the cross-sectional area, and collagen fraction volume ratio were performed using Image J 1.29, a free software program.

Western Blot Analysis-Activities of extracellular signal-regulated kinase1/2 (ERK1/2), ERK5, also referred to as big mitogen-activated protein (MAP) kinase 1, and Smad2 were measured by Western blot analysis as described previously (14, 15). For evaluation of activated ERK1/2, ERK5, and Smad2, phosphospecific ERK1/2 antibody, phosphospecific ERK5 antibody, and phosphospecific Smad2 antibody (Cell Signaling Technology, Beverly, MA) were used, respectively. For Western blot analysis, protein extracts (30 µg for ERK1/2 and ERK5 and 150 µg for Smad2) from the hearts of WT and ARKO mice were boiled for 5 min in Laemmli sample buffer and then run on SDS-PAGE. The protein extracts were then transferred to a nitrocellulose membrane (HybondTM-ECL, Amersham Biosciences). The membrane was blocked for 1 h at room temperature with 5% bovine serum albumin in phosphate-buffered saline/Tween 20. The blots were incubated overnight at 4 °C with antibodies for phosphospecific ERK1/2, phosphospecific ERK5, and phosphospecific Smad2, followed by incubation for 1 h with anti-rabbit secondary antibody (horseradish peroxidase-conjugate). Immunoreactive bands were visualized using enhanced chemiluminescence with ECL reagent (Amersham Biosciences) treatment and exposure to Hyperfilm-ECL. The intensity of the bands was measured using Image J version 1.29.

Northern Blots Analysis-Procedures were performed as previously described (16). In brief, total RNA was isolated from both the right and left ventricles with TRIzol (Invitrogen). RNA concentrations were measured spectrophotometrically at 260 nm, and samples were stored in diethyl dicarbonate-treated water at -80 °C. Approximately 20 µg of total RNA from each sample was fractionated on 1% formaldehyde-agarose gels and transferred to Hybond nylon membranes (Amersham Biosciences) by capillary action in a high salt solution (20 x SSC). Blots were prehybridized in a hybridization solution for 1 h at 42 °C, followed by overnight hybridization with digoxigenin-labeled specific oligonucleotide probes (DIG Northern Starter Kit, Roche Applied Science). Blots were washed twice in 2 x SSC/0.1% SDS at room temperature for 5 min and then washed twice in 0.2 x SSC/0.1% SDS at 68 °C for 15 min before exposure to x-ray film. Evaluation of mRNA levels encoding A-type natriuretic peptide (ANP), B-type natriuretic peptide (BNP), -myosin heavy chain (MHC), -myosin heavy chain (MHC), and collagen types I and III was performed. Quantification of mRNA levels was estimated after correction for loading differences by measuring the amount of 28 S rRNA. The intensity of the bands was also measured using Image J version 1.29. Oligonucleotide primers for ANP, BNP, MHC, MHC, and collagen types I and III are shown in Table I.

TABLE I

Primer sequences for mRNA analyses Sequences are listed 5' to 3'.

Quantitative Real-time PCR by SYBR Green Detection Method-The mRNA levels of angiotensin II type la receptor (AT1aR), angiotensin II type 2 receptor (AT2R), and transforming growth factor-1 (TGF-1) were evaluated by quantitative real-time PCR. In brief, total RNA isolated from heart tissue was used for cDNA synthesis. A cDNA was prepared from 1 µg of total RNA using SuperScript II reverse transcriptase (Invitrogen), used for random hexamers, dNTPs, and first-strand cDNA synthesis, according to the manufacturer's instructions. The amplification reaction was performed in a final volume of 20 µl in 96-well optical reaction plates (Applied Biosystems, Foster City, CA). The PCR mixture contained 50 ng of cDNA, 1 µl of 0.1 nM forward and reverse primer mix, and 13 µl of SYBR Green PCR Master Mix (Applied Biosystems), which contains the fluorescent dye SYBR Green. Assays were performed with an ABI Prism 7500 Sequence Detector (Applied Biosystems). The dye exhibits fluorescence enhancement upon binding to double-stranded DNA, and the enhancement of fluorescence is proportional to the initial concentration of the cDNA. Amplification included one stage of 2 min at 50 °C and one stage of 10 min at 95 °C followed by 40 cycles of a three-step loop: 30 s at 95 °C, 30 s at 54 °C, and 30 s at 72 °C. A melting curve was used to identify a temperature where only the amplicon, and not primer dimers, accounted for the SYBR green-bound fluorescence. Results were analyzed with the SDS7500 software, and all values were normalized to levels of the glyceraldehyde-3-phosphate dehydrogenase (G3PDH). Oligonucleotide primers used in this study are shown in Table I.

Statistical Analysis-Values for each parameter within a group were expressed as a mean ± S.E. For comparisons among groups, statistical significance was assessed using a one-way analysis of variance, and the significance of each difference was determined by post hoc testing using Tukey-Kramer's method. These analyses were performed on an Apple Macintosh computer with the use of Excel (Microsoft X) and Stat View statistical package (Stat View 5.0, SAS Institute Inc.) (17). Statistical significance was considered at p

RESULTS

Blood Pressure and Heart Rate-Basal levels of systolic blood pressure in WT mice were similar to those of ARKO mice. Systolic blood pressure levels in both WT and ARKO mice were significantly increased by Ang II stimulation, but there was no statistical difference between the two groups (Table II). There was no significant difference in heart rate between WT and ARKO mice, and Ang II stimulation did not affect heart rate in either group (Table II).

TABLE II

Systolic blood pressure, heart rate, and heart-to-body weight ratio Values are means ± S.E. Each group, n = 40.

Reduced Cardiac Mass in ARKO Male Mice with or without Ang II Stimulation-Gross appearance of the isolated heart was smaller in ARKO mice than in WT mice (Fig. 1A), and the HW/BW was significantly lower in ARKO mice than in WT mice (Table II), whereas there was no obvious difference in cardiac size or HW/BW between these mice until the age of 6 weeks (data not shown). Although Ang II stimulation caused an increase in both cardiac size (Fig. 1, A and B) and the HW/BW ratio (Table II) in WT and ARKO mice, these values were still lower in ARKO mice than in WT mice. Cross-sections of the heart demonstrated that LV volume and wall thickness in ARKO mice were reduced compared with those in WT mice (Fig. 1B). In addition, Ang II stimulation could elicit a prominent cardiac hypertrophy in WT mice, whereas the cardiac LV volume and wall thickening after Ang II stimulation was still lower in ARKO mice compared with those in WT mice (Fig. 1B).

FIG. 1.

Macro- and microscopic analyses in WT and ARKO male mice with or without Ang II stimulation. A, appearance of the isolated hearts; B, Masson-Trichrome-stained LV cross-sections on the papillary muscle level; C, histological sections of Masson-Trichrome-stained cardiac tissue for the determination of the cross-sectional area and interstitial fibrosis; D, myofibrillar cross-sectional areas; E, interstitial collagen fractions in WT (white bars) and ARKO (black bars) male mice. Values are expressed as mean ± S.E. *, p n = 12.

Histomorphometric analyses of the LV tissues showed that the cross-sectional area of cardiomyocytes without Ang II stimulation was significantly smaller in ARKO mice than in WT mice (Fig. 1D). Although Ang II stimulation caused an increase in the cross-sectional area of the cardiomyocytes in both WT and ARKO mice, the cross-sectional area after Ang II stimulation was again smaller in ARKO mice than in WT mice (Fig. 1D).

Exacerbated Cardiac Fibrosis by Ang II Stimulation in ARKO Male Mice-The collagen fraction volume ratio calculated from histomorphometric analyses of Masson-Trichrome-stained specimens revealed that cardiac fibrosis was faintly present in LV tissues of WT and ARKO mice without Ang II stimulation. Ang II stimulation elicited a markedly enhanced fibrotic change in LV tissues of ARKO mice compared with those of WT mice (Fig. 1, B, C, and E). However, Ang II administration did not cause an obvious progression of cardiac fibrosis in both WT and ARKO mice when the experiments were conducted at 8 weeks instead of 25 weeks of age (data not shown).

Analyses of Cardiac Structure-Echocardiographic studies revealed that Ang II stimulation caused a significant increase in the values of AW and PW in both WT and ARKO mice (mean ± S.E. mm; AW: 0.86 ± 0.03 to 1.15 ± 0.01 in WT and 0.60 ± 0.02 to 0.70 ± 0.02 in ARKO mice; PW: 0.88 ± 0.03 to 1.13 ± 0.03 in WT and 0.68 ± 0.02 to 0.72 ± 0.02 in ARKO mice), whereas there was no statistically significant change in LVM/BW and RWT by Ang II stimulation in ARKO mice. Furthermore, although the values of LVDd and LVDs were decreased in Ang II-stimulated WT mice due to their concentric hypertrophy, these values did not change or even slightly increase in ARKO mice by Ang II stimulation (Fig. 2).

Ang II-stimulated Cardiac Dysfunction in ARKO Male Mice-We also evaluated the cardiac performance of these mice using echocardiography. Although left ventricular FS, a marker of systolic function, was not significantly different between WT and ARKO mice, Ang II stimulation significantly attenuated LV systolic function in ARKO mice compared with WT mice (Fig. 2).

Ang II-stimulated Cardiac ERK1/2 and ERK5 Activations Were Decreased in ARKO Male Mice-Because MAP kinase pathways have been shown to be involved in cardiac hypertrophy (18, 19) and function (20), we examined effects of Ang II stimulation on ERK1/2 and ERK5 activities. Ang II stimulation caused a significant increase in cardiac ERK1/2 and ERK5 phosphorylation in WT mice, whereas Ang II stimulation did not significantly enhance MAP kinase phosphorylation in ARKO mice (Fig. 3). Phosphorylation of other MAP kinases, c-Jun NH2-terminal kinase and p38, by Ang II were not observed in either WT or ARKO mice (data not shown). These results suggest that the blunted response to Ang II stimulation in ERK1/2 and ERK5 activities may be at least in part related to the aberrant cardiac hypertrophic response and cardiac dysfunction in ARKO mice.

FIG. 2.

Upper panel, representative echocardiogram of LV wall motion in WT and ARKO male mice with or without Ang II stimulation. Lower panel, echocardiographic measurements of LVDd, LVM/BW, RWT, and FS in WT and ARKO male mice with or without Ang II stimulation. LVDd, left ventricular diastolic dimension; LVM, left ventricular mass; BW, body weight; RWT, relative wall thickness; FS, fractional shortening. Values are expressed as mean ± S.E. *, p n = 25.

Aberrant Gene Expression of Cardiac Remodeling Factors in ARKO Male Mice-As shown in Fig. 4, the basal gene expression levels of BNP, MHCs, and types I and III collagen were not different between WT and ARKO mice. The ANP mRNA level was slightly lower in ARKO mice than in WT mice. Although Ang II stimulation markedly enhanced the expression levels of ANP and BNP mRNA in both WT and ARKO mice, the expression level of ANP mRNA was increased more in ARKO mice than in WT mice. Ang II stimulation did not affect MHC mRNA levels in either WT or ARKO mice, but enhanced MHC mRNA expression only in WT mice. Ang II stimulation enhanced both type I and III collagen mRNA expression levels in WT and ARKO mice, but the enhancement was more pronounced in ARKO mice. Although there were no significant differences in the AT1aR and AT2R mRNA levels between WT and ARKO mice with or without Ang II stimulation, ARKO mice showed a tendency for higher expression in these mRNA levels than WT mice in the presence or absence of Ang II stimulation (Fig. 5).

TGF-1 Expression and Smad Pathway Were Activated in ARKO Mice by Ang II Stimulation-TGF-1 has been identified as a contributor of cardiac fibrosis (21), and Ang II is known to affect TGF-1 expression (22). Upon binding of TGF-1 to its receptor, phosphorylation of Smad2 and its subsequent translocation to the nucleus is a critical step in TGF-1 signaling pathway (23, 24). Therefore, we examined the effects of Ang II on TGF-1 expression and Smad2 activation. Although Ang II stimulation significantly enhanced cardiac TGF-1 mRNA levels in both WT and ARKO mice, the degree of enhancement of its gene expression was more augmented in ARKO mice than in WT mice (Fig. 5). Consistent with the increase in TGF-1 mRNA expression, Ang II stimulation also caused a significant increase in cardiac Smad2 phosphorylation in both WT and ARKO mice with more Smad2 phosphorylation in ARKO than in WT mice (Fig. 6).

FIG. 3.

Effects of AR inactivation on cardiac ERK1/2 and ERK5 phosphorylation in WT and ARKO male mice with or without Ang II stimulation. ERK1/2 and ERK5 phosphorylation of the hearts were measured by Western blot analysis as described under "Experimental Procedures." The upper panels show the representative blots of phosphorylated forms of ERK1/2 and ERK5, and the middle panels show the blots of total (phosphorylated and unphosphorylated) ERK1/2 and ERK5, respectively. Lower panels show the densitometric analysis of phosphorylated ERK1/2 and ERK5 of WT (white bars) and ARKO (black bars) male mice. Values were normalized by arbitrarily setting the densitometry of control (without Ang II in WT male mice) to 1.0. Values are expressed as mean ± S.E. *, p n = 18.

DISCUSSION

Increased cardiac mass, used synonymously with cardiac hypertrophy, is one of the important cardiovascular risk factors (25). Although appropriate cardiac hypertrophy is an adaptive response to several forms of heart disease, excessive cardiac hypertrophy causes pathological cardiac remodeling. Cardiac mass increases at much greater rates in males than in females from puberty and throughout life, even after allometric adjustment for gender differences in overall body size (26, 27). The gender difference of LV mass has led to the hypothesis that sex hormones, such as androgen and estrogen, influence LV mass (25). In fact, estrogen has a preventive effect on cardiac hypertrophy (28-30), whereas androgen causes cardiac hypertrophy (13, 25, 28-30). In experimental animals, cardiac hypertrophy is suppressed by castration (13, 30, 31) and anti-androgens (32). Serum levels of testosterone, dehydroepiandrosterone, and its sulfate conjugate dehydroepiandrosterone sulfate decrease in males with chronic heart failure (33-36), and administration of testosterone results in an improvement of cardiac function in male patients with congestive heart failure (37). However, it is still unclear whether androgen plays a beneficial role in the regulation of cardiac structure and function.

To clarify the physiological roles of androgen on cardiac structure and function, we used ARKO male mice established using the Cre-loxP system, which allows the AR-null mutation to be passed on to offspring (8, 9). The present study demonstrated that cardiac volume and wall thickness were smaller in ARKO mice than those in WT mice without any difference in blood pressure or heart rate between these mice. The physiological and pathophysiological significance of androgen in male cardiac morphology and function was also examined. Our results indicate that androgen action is required for sufficient cardiac growth with adequate myofiber size, regardless of the presence or absence of cardiac stress in male mice.

Experimental and clinical observations indicate that Ang II stimulation induces hypertension (38, 39), pathological cardiac remodeling (40, 41), and heart failure (42, 43). When Ang II stimulation causes pressure or volume overload of the heart, the resulting cardiac hypertrophy is initially a compensatory response to preserve cardiac performance against cardiac load. It is also postulated that the concentric geometric remodeling with a reduction in the LV chamber size relative to wall thickness is an adaptation to preserve the LV pump function (44). The present study demonstrated that Ang II-stimulated ARKO male mice exhibit an aberrant cardiac hypertrophic response of the LV wall. Therefore, our results indicate that AR is required for the physiological hypertrophy of normal postnatal cardiac development in male mice, and for adaptive responses to cardiac stress such as Ang II stimulation.

FIG. 4.

Aberrant gene expression patterns of cardiac remodeling factors in ARKO male mice with or without Ang II stimulation. The left panel demonstrates the representative Northern blots of cardiac remodeling factors in WT and ARKO male mice with or without Ang II stimulation. The right panel shows the results of densitometric analyses of each parameter in WT (white bars) and ARKO (black bars) male mice. Values were normalized by arbitrarily setting the densitometry of control (WT male mice without Ang II) to 1.0. Values are expressed as mean ± S.E. *, p **, p n = 18.

FIG. 5.

Effects of AR deficiency on the gene expression of AT1aR (left), AT2R (middle), and TGF-1(right) with or without Ang II stimulation. The real-time PCR analyses of each parameter were performed in WT (white bars) and ARKO (black bars) male mice. Values were normalized by arbitrarily setting the measurement of control (WT male mice without Ang II) to 1.0. Values are expressed as mean ± S.E. *, p n = 12.

FIG. 6.

Cardiac Smad2 phosphorylation in WT and ARKO male mice with or without Ang II stimulation. Phosphorylated Smad2 levels of the heart were measured by Western blot analysis as described under "Experimental Procedures." The left panels show the representative blots of phosphorylated forms of Smad2, and the blots of total (phosphorylated and unphosphorylated) Smad2. The right panel shows the results of densitometric analysis concerning phosphorylated Smad2 in WT (white bars) and ARKO (black bars) male mice. Values were normalized by arbitrarily setting the densitometry of control (WT male mice without Ang II) to 1.0. Values are expressed as mean ± S.E., *p n = 6.

A critical role for ERK1/2 and ERK5 has been demonstrated in transgenic mice in the development of cardiac hypertrophy (18, 19). In the present study, we found that ERK1/2 and ERK5 were activated by Ang II stimulation in WT male mice, whereas their activities were lower in ARKO male mice after Ang II stimulation. These results are consistent with the macro- and microscopic observations of WT and ARKO male mice hearts, and suggest that ERK1/2 and/or ERK5 activation might be involved in Ang II-induced cardiac hypertrophy. It has been reported that Ang II infusion causes cardiac hypertrophy in rats with a concomitant increase in ERK1/2 activity (45). In addition, ERK5 activation has been shown to cause hypertrophy of cardiomyocytes (46) as well as the inhibition of endothelial cell death (47). Thus, the blunted ERK1/2 and ERK5 activation may be the mechanism whereby ARKO male mice exhibit reduced cardiac size with aberrant hypertrophic response to Ang II stimulation. However, further studies are needed to clarify the precise role of MAP kinases in AR-mediated intracellular signaling in the heart.

The present study demonstrated that the mRNA level of ANP in ARKO mice was reduced compared with WT mice. This result is consistent with the evidence that androgens increase ANP secretion via an AR-mediated mechanism in cultured rat myocytes (11). However, Ang II stimulation caused prominent enhancement of ANP gene expression in ARKO mice more than WT mice. If androgen actions were lacking under cardiac stress, it may be required that some ANP enhancers, including mechanical stress, strongly promote the ANP expression for supporting the cardiac performance. We also found the reduction of MHC gene expression in Ang II-stimulated ARKO mice compared with WT mice with Ang II loading. An up-regulation of the MHC gene relative to the MHC gene is observed in clinical conditions such as cardiac hypertrophy, cardiomyopathy, and congestive heart failure (48, 49). Because this up-regulation of the gene has been recognized as a compensatory response during cardiac remodeling, we speculate that aberrant MHC gene expression in ARKO mice is associated with impairment of adaptive cardiac hypertrophy under the condition of hypertrophic stress. Further investigation is needed to clarify this issue. And we found tendencies of higher AT1aR and AT2R gene expression in ARKO mice compared with WT mice, however, there were no statistical differences among those groups. Thus, we could conclude at least in this situation that AT1aR or AT2R expression levels are not a major cause of impaired cardiac hypertrophic response after Ang II stimulation in ARKO mice.

In addition to insufficient cardiac growth and aberrant hypertrophic responses, the present study demonstrated an enhanced cardiac fibrosis with up-regulation of collagen I and III gene expression in ARKO male mice after Ang II infusion. It has been reported that Ang II-induced proliferation of cardiac fibroblasts and an increase of collagen deposition contribute to an increase in cardiac muscle stiffness and the development of diastolic and systolic dysfunctions (50, 51). In fact, the present echocardiographic examination showed that the significant impairment of systolic function was observed in only ARKO male mice with Ang II stimulation. We also found that Ang II stimulation enhanced cardiac TGF-1 and Smad2 phosphorylation in ARKO mice more than in WT mice. TGF-1 is a powerful stimulator of the production of fibrillar collagens and other extracellular matrix components in a variety of cell types (52). A major signaling pathway after TGF-1 receptor activation is phosphorylation of Smad2/3 pathway (24). Hao et al. (53) showed that the levels of cardiac Smad2 are up-regulated after myocardial infarctions and that phosphorylation of Smad2 is attenuated by an Ang II type 1 receptor blockade. In addition, Kyprianou et al. (54, 55) revealed that endogenous androgens suppress the TGF- expression and Smad2/3 activation in the prostates of rats. They also showed that castration causes robust expression of TGF- and activation of Smad2/3 in the prostate (54, 55). Those previous reports and our results suggest that androgens have a protective role against AngII-stimulated cardiac fibrosis via suppression of TGF-1-Smad signaling. Taken together, the present observations provide novel in vivo evidence that the androgen-AR system plays a protective role against Ang II-induced aberrant cardiac remodeling that leads to systolic dysfunction.

ACKNOWLEDGMENTS

We thank Kazue Ishikawa for her technical help.

【參考文獻(xiàn)】
  Mooradian, A. D., Morley, J. E., and Korenman, S. G. (1987) Endocr. Rev. 8, 1-28

Wilson, J. D. (1999) Endocr. Rev. 20, 726-737

Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schutz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., and Evans, R. M. (1995) Cell 83, 835-839

Takeyama, K., Ito, S., Yamamoto, A., Tanimoto, H., Furutani, T., Kanuka, H., Miura, M., Tabata, T., and Kato, S. (2002) Neuron 35, 855-864

McKenna, N. J., and O'Malley, B. W. (2002) Cell 108, 465-474

Glass, C. K., and Rosenfeld, M. G. (2000) Genes Dev. 14, 121-141

Yanagisawa, J., Kitagawa, H., Yanagida, M., Wada, O., Ogawa, S., Nakagomi, M., Oishi, H., Yamamoto, Y., Nagasawa, H., McMahon, S. B., Cole, M. D., Tora, L., Takahashi, N., and Kato, S. (2002) Mol. Cell 9, 553-562

Sato, T., Matsumoto, T., Yamada, T., Watanabe, T., Kawano, H., and Kato, S. (2003) Biochem. Biophys. Res. Commun. 300, 167-171

Kawano, H., Sato, T., Yamada, T., Matsumoto, T., Sekine, K., Watanabe, T., Nakamura, T., Fukuda, T., Yoshimura, K., Yoshizawa, T., Aihara, K., Yamamoto, Y., Nakamichi, Y., Metzger, D., Chambon, P., Nakamura, K., Kawaguchi, H., and Kato, S. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 9416-9421

Sato, T., Matsumoto, T., Kawano, H., Watanabe, T., Uematsu, Y., Sekine, K., Fukuda, T., Aihara, K., Krust, A., Yamada, T., Nakamichi, Y., Yamamoto, Y., Nakamura, T., Yoshimura, K., Yoshizawa, T., Metzger, D., Chambon, P., and Kato, S. (2004) Proc. Natl. Acad. Sci. U. S. A. 101, 1673-1678

Marsh, J. D., Lehmann, M. H., Ritchie, R. H., Gwathmey, J. K., Green, G. E., and Schiebinger, R. J. (1998) Circulation 98, 256-261

Golden, K. L., Marsh, J. D., Jiang, Y., Brown, T., and Moulden, J. (2003) Am. J. Physiol. 285, E449-E453

Li, Y., Kishimoto, I., Saito, Y., Harada, M., Kuwahara, K., Izumi, T., Hamanaka, I., Takahashi, N., Kawakami, R., Tanimoto, K., Nakagawa, Y., Nakanishi, M., Adachi, Y., Garbers, D. L., Fukamizu, A., and Nakao, K. (2004) Endocrinology 145, 951-958

Nishiyama, A., Yao, L., Nagai, Y., Miyata, K., Yoshizumi, M., Kagami, S., Kondo, S., Kiyomoto, H., Shokoji, T., Kimura, S., Kohno, M., and Abe, Y. (2004) Hypertension 43, 841-848

Suzaki, Y., Yoshizumi, M., Kagami, S., Nishiyama, A., Ozawa, Y., Kyaw, M., Izawa, Y., Kanematsu, Y., Tsuchiya, K., and Tamaki, T. (2004) Kidney Int. 65, 1749-1760

Aihara, K., Azuma, H., Akaike, M., Ikeda, Y., Yamashita, M., Sudo, T., Hayashi, H., Yamada, Y., Endoh, F., Fujimura, M., Yoshida, T., Yamaguchi, H., Hashizume, S., Kato, M., Yoshimura, K., Yamamoto, Y., Kato, S., and Matsumoto, T. (2004) J. Biol. Chem. 279, 35798-35802

Aihara, K., Azuma, H., Takamori, N., Kanagawa, Y., Akaike, M., Fujimura, M., Yoshida, T., Hashizume, S., Kato, M., Yamaguchi, H., Kato, S., Ikeda, Y., Arase, T., Kondo, A., and Matsumoto, T. (2004) Circulation 109, 2761-2765

Bueno, O. F., De Windt, L. J., Tymitz, K. M., Witt, S. A., Kimball, T. R., Klevitsky, R., Hewett, T. E., Jones, S. P., Lefer, D. J., Peng, C. F., Kitsis, R. N., and Molkentin, J. D. (2000) EMBO J. 19, 6341-6350

Nicol, R. L., Frey, N., Pearson, G., Cobb, M., Richardson, J., and Olson, E. N. (2001) EMBO J. 20, 2757-2767

Harris, I. S., Zhang, S., Treskov, I., Kovacs, A., Weinheimer, C., and Muslin, A. J. (2004) Circulation 110, 718-723

Weber, K. T. (1997) Semin. Nephrol. 17, 467-491

Campbell, S. E., and Katwa, L. C. (1997) J. Mol. Cell Cardiol. 29, 1947-1958

Massague, J., and Weis-Garcia, F. (1996) Cancer Surv. 27, 41-64

Massague, J. (2000) Nat. Rev. Mol. Cell. Biol. 1, 169-178

Hayward, C. S., Webb, C. M., and Collins, P. (2001) Lancet 357, 1354-1356

Hayward, C. S., Kelly, R. P., and Collins, P. (2000) Cardiovasc. Res. 46, 28-49

Leinwand, L. A. (2003) J. Clin. Invest. 112, 302-307

Malhotra, A., Buttrick, P., and Scheuer, J. (1990) Am. J. Physiol. 259, H866-H871

Weinberg, E. O., Thienelt, C. D., Katz, S. E., Bartunek, J., Tajima, M., Rohrbach, S., Douglas, P. S., and Lorell, B. H. (1999) J. Am. Coll. Cardiol. 34, 264-273

Cavasin, M. A., Sankey, S. S., Yu, A. L., Menon, S., and Yang, X. P. (2003) Am. J. Physiol. 284, H1560-H1569

Morano, I., Gerstner, J., Ruegg, J. C., Ganten, U., Ganten, D., and Vosberg, H. P. (1990) Circ. Res. 66, 1585-1590

Baltatu, O., Cayla, C., Iliescu, R., Andreev, D., Jordan, C., and Bader, M. (2002) J. Am. Soc. Nephrol. 13, 2681-2687

Anker, S. D., Chua, T. P., Ponikowski, P., Harrington, D., Swan, J. W., Kox, W. J., Poole-Wilson, P. A., and Coats, A. J. (1997) Circulation 96, 526-534

Moriyama, Y., Yasue, H., Yoshimura, M., Mizuno, Y., Nishiyama, K., Tsunoda, R., Kawano, H., Kugiyama, K., Ogawa, H., Saito, Y., and Nakao, K. (2000) J. Clin. Endocrinol. Metab. 85, 1834-1840

Kiilavuori, K., Naveri, H., Leinonen, H., and Harkonen, M. (1999) Eur. Heart J. 20, 456-464

Kontoleon, P. E., Anastasiou-Nana, M. I., Papapetrou, P. D., Alexopoulos, G., Ktenas, V., Rapti, A. C., Tsagalou, E. P., and Nanas, J. N. (2003) Int. J. Cardiol. 87, 179-183

Pugh, P. J., Jones, T. H., and Channer, K. S. (2003) Eur. Heart J. 24, 909-915

Ishibashi, M., Hiasa, K. I., Zhao, Q., Inoue, S., Ohtani, K., Kitamoto, S., Tsuchihashi, M., Sugaya, T., Charo, I. F., Kura, S., Tsuzuki, T., Ishibashi, T., Takeshita, A., and Egashira, K. (2004) Circ. Res. 94, 1203-1210

Kobori, H., Prieto-Carrasquero, M. C., Ozawa, Y., and Navar, L. G. (2004) Hypertension 43, 1126-1132

Izumiya, Y., Kim, S., Izumi, Y., Yoshida, K., Yoshiyama, M., Matsuzawa, A., Ichijo, H., and Iwao, H. (2003) Circ. Res. 93, 874-883

Ichihara, S., Senbonmatsu, T., Price, E., Jr., Ichiki, T., Gaffney, F. A., and Inagami, T. (2001) Circulation 104, 346-351

Muller, D. N., Mullally, A., Dechend, R., Park, J. K., Fiebeler, A., Pilz, B., Loffler, B. M., Blum-Kaelin, D., Masur, S., Dehmlow, H., Aebi, J. D., Haller, H., and Luft, F. C. (2002) Hypertension 40, 840-846

Cohn, J. N., and Tognoni, G. (2001) N. Engl. J. Med. 345, 1667-1675

Aurigemma, G. P., Silver, K. H., Priest, M. A., and Gaasch, W. H. (1995) J. Am. Coll. Cardiol. 26, 195-202

Yano, M., Kim, S., Izumi, Y., Yamanaka, S., and Iwao, H. (1998) Circ. Res. 83, 752-760

Nakaoka, Y., Nishida, K., Fujio, Y., Izumi, M., Terai, K., Oshima, Y., Sugiyama, S., Matsuda, S., Koyasu, S., Yamauchi-Takihara, K., Hirano, T., Kawase, I., and Hirota, H. (2003) Circ. Res. 93, 221-229

Hayashi, M., Kim, S. W., Imanaka-Yoshida, K., Yoshida, T., Abel, E. D., Eliceiri, B., Yang, Y., Ulevitch, R. J., and Lee, J. D. (2004) J. Clin. Invest. 113, 1138-1148

Gupta, M., and Zak, R. (1992) Am. J. Physiol. 262, R346-R349

Boluyt, M. O., Bing, O. H., and Lakatta, E. G. (1995) Eur. Heart J. 16, Suppl. N, 19-30

Jalil, J. E., Doering, C. W., Janicki, J. S., Pick, R., Shroff, S. G., and Weber, K. T. (1989) Circ. Res. 64, 1041-1050

Ryoke, T., Gu, Y., Mao, L., Hongo, M., Clark, R. G., Peterson, K. L., and Ross, J., Jr. (1999) Circulation 100, 1734-1743

Massague, J. (1990) Annu. Rev. Cell Biol. 6, 597-641

Hao, J., Wang, B., Jones, S. C., Jassal, D. S., and Dixon, I. M. (2000) Am. J. Physiol. 279, H3020-H3030

Kyprianou, N., and Isaacs, J. T. (1988) Endocrinology 123, 2124-2131

Kyprianou, N., and Isaacs, J. T. (1989) Mol. Endocrinol. 3, 1515-1522